Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

December 23, 2023

https://www.prnewswire.com/news-releases/tyra-biosciences-doses-first-patient-with-tyra-200-and-provides-positive-updates-on-tyra-300-302021502.html

– Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200- 
– Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300-
– Received FDA feedback on TYRA-300 Phase 2 ACH study: IND submission planned for 2H 2024-

Read more at prnewswire.com

Related news for (TYRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.